FDA Draft Guidance On Drug Development For Early Alzheimer's A Call For Action On Biomarkers
FDA’s new draft guidance on developing drugs to treat people in the early stages of Alzheimer’s disease offers options for trial design, but without biomarkers to accurately diagnose the disease and track its progression, a trial could be doomed from the start.
You may also be interested in...
Anti-beta amyloid antibodies from Lilly, Biogen Idec and Roche took center stage at the recent Alzheimer’s Association International Congress, but as a new PhRMA analysis shows, getting to the development finish line is rare – with 30 failures for every one success.
New data analyses at the Alzheimer’s Association International Congress spur some optimism, but analysts advise caution about whether they will actually translate into clinically meaningful benefits in pivotal trials.
Russell Katz will retire following a 30-year career at FDA; his departure comes as the agency is embarking on new efforts to encourage drug development for Alzheimer’s disease and amyotrophic lateral sclerosis.